Application Note: Streamlining the Antibody Discovery Workflow at ModiQuest Research
Breakthroughs in molecular engineering and antibody humanization, have resulted in monoclonal antibodies (mAbs) becoming one of the fastest-growing classes of biopharmaceuticals for multiple clinical indications.
This highly competitive landscape necessitates the need for rapidly developing next-generation antibodies against new challenging targets with the improved mechanism of action, pharmacokinetics, and delivery system.
Current antibody screening tools such as ELISA only report on binding, one antigen at a time, hence they are time-consuming and utilize large amounts of the target protein. This application note highlights how the Intellicyt® iQue Screener platform enabled scientists at ModiQuest Research to significantly reduced their lead discovery time while conserving valuable samples and cutting down reagent cost.